Opinion|Videos|January 5, 2026
Exploring Triplet Therapies in IDH-Mutated AML
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss data from MD Anderson Cancer Center on triplet therapies in AML with IDH mutations.
Advertisement
Episodes in this series
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, review data from a study published at The University of Texas MD Anderson Cancer Center evaluating triplet therapy approaches in patients with IDH-mutated acute myeloid leukemia (AML). They discuss early efficacy signals, response depth, and tolerability observed with combinations incorporating IDH inhibitors. DiNardo and Altman place these findings in context of evolving treatment paradigms for molecularly defined AML subsets.
Advertisement
Related to this article
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Sylvester cancer researchers became wildland firefighters themselves to study, from the inside, cancer risks tied to the job.
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
June’s GI Rewind: CRC, Gastric Cancer See Several “Firsts” With FDA Review of Adjuvant IO, Global Approval of BRAF-Targeted and CAR T-Cell Therapies
4
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
5